Skip to main content
Premium Trial:

Request an Annual Quote

Decode's Q2 Revenue Falls 27 Percent as Loss Narrows

NEW YORK (GenomeWeb News) - Decode Genetics today said second-quarter revenues fell by 27 percent as R&D spending grew 10 percent and losses fell 11 percent.
 
Total receipts for the three months ended June 30 fell to $7.6 million from $10.4 million year over year. The company attributed the decrease in revenue to the conclusion of its diagnostics partnership with Roche in 2006.
 
R&D spending rose to $14.5 million from $13.2 million year over year. Decode said the rising costs are due to “the advance of our drug development programs, the launch of our first DNA-based tests for gauging individual risk of common diseases, and the acceleration of our gene and target discovery work.”
 
The company reduced its net loss to $16.2 million from $18.3 million in the year-ago period.
 
Decode said it had around $137.2 million in cash, cash equivalents, and investments as of June 30.
 
Company CEO Kari Stefansson said in a statement that Decode ended the quarter with a “strengthened cash position" that it will use to fund further product development.
 
Stefansson added that the company recently launched DNA-based tests for assessing the risk of type 2 diabetes and the risk of atrial fibrillation and stroke, and said Decode's compound for heart attack treatment and its anti-platelet therapeutic have shown encouraging clinical results.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.